Siegfried at a Glance April 2020
About Us
Who are we? › Company founded more than 140 years ago › Production of active pharmaceutical ingredients (Drug Substance ), intermediates and finished dosage forms (Drug Products) › Unique selling proposition (USP): integrated service provider for development and manufacturing to the chemical and pharmaceutical industry › Number of employees (FTE): approx. 2500 › World-class service partner regarding Quality and Compliance › Listed on the Swiss Stock Exchange SIX 3
Why Siegfried? › Bringing together our more than 140 years Pharma and Chemical heritage , we offer as an integrated partner benefit to our customers with more synergy, expertise and value. › We offer integrated supply of APIs and finished products . Drug Process Dosage Clinical Marketing & Intermediates API Commercial discovery development formulation supplies Distribution Integration DS und DP Drug Substances (DS) Drug Products (DP) › Toughened stance by FDA: Siegfried for several years inspected with «no action indicated». 4
Our production network offers a unique combination of flexibility and integration for both, innovative and generic products 5
Our Mission Our Vision Our Values
Siegfried does matter to customers, patients and society – every day, everywhere Siegfried API portfolio › Siegfried supplies approx. 200 APIs out of 1500 APIs 200 approved by the FDA , thereby acting as a significant 1,300 source to patients’ therapy continuity Others › Based on our current portfolio, Siegfried serves approx. 40 million patients annually › Significant share of the annual global caffeine supply -> up to 1b people get in contact with Siegfried products each year Source: EvaluatePharma World Preview 2018, FDA orange book, Siegfried estimates 7
Our mission: we do matter to customers, patients and society «With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide» 8
Our vision: we aim for industry leadership «Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because… … we are the strongest team running the most competitive network» 9
Our values: we strive for outstanding performance Excellence «Our values and leadership principles «We excel in everything we do» are the basis to build the strongest team in the industry» Passion «We deeply care about what we do and how we do it» Integrity «We act responsibly, reliably, respectfully and live up to our own standards» Quality «We do it right first time» Sustainability «We do not only think about tomorrow, but far beyond» 10
Our leadership values are the basis to build the strongest team in the industry Ensure Empower quality people Manage Deliver service and performance value Focus on Lead and develop customers people Foster Drive business innovation growth Excellence Manage Lead Passion change and Integrity and develop innovation Quality organization Excel Lead change Sustainability operationally process Embody and exemplify values Drive and business results Make Act standards decisions reliably Drive Be a role implementation model 11
Our History
History 1873 Pharmacist Samuel Benoni Siegfried founds a company with 12 employees as a supplier to pharmacies 1904 Conversion into a joint stock corporation 1928 Founding of Ganes Chemical Works, Inc. (NJ, USA) 1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 Focus on development and custom manufacturing 13
History 2001 Building of two core divisions: Siegfried and Sidroga Integration of Ganes into the Siegfried Group = Siegfried (USA) Inc. 2005 Acquisition of Penick Corporation in New Jersey (USA) 2007 Launch of a new pharmaceutical production facility in Malta Sale of the Sidroga Division Sale of the biotech activities 2008 Sale of the pharmaceutical production site in Zofingen 14
History 2010 Definition of new strategy “Transform” 2012 Acquisition of Alliance Medical Products (AMP) in Irvine (CA, USA) 2013 Construction of new production site Nantong (CN) and Zofingen (CH) 2014 Acquisition of Hameln Pharma in Hameln (DE) 2015 Acquisition of BASF sites in Minden (DE), Evionnaz (CH) and St. Vulbas (FR) 2016 Definition of new strategy “Evolve” 2018 Acquisition of the drug product manufacturing facility of Arena in Zofingen (CH) 15
Our Management
Management – Board of Directors › Dr. Martin Schmid › Dr. Andreas Casutt › Chairman › Colin Bond › Ulla Schmidt › Prof. Dr. Wolfram Carius › Isabelle Welton › Reto A. Garzetti 17
Management – Executive Committee › Arnoud M. Middel › Dr. Wolfgang Wienand › Global Head Human › Chief Executive Officer Resources › Dr. Reto Suter › Jürgen Roos › Chief Financial Officer › Chief Scientific Officer › Marianne Späne › Dr. René Imwinkelried › Global Head Business › Global Head Technical Development, Marketing & Sales Operations 18
Financials
Net Sales CHF million 2019 2018 Change Drug Substances 638.6 595.5 +7.2% (+9.0% in LC) Drug Products 194.9 198.8 -2.0% (+0.5% in LC) Total 833.5 794.3 +4.9% (+6.9% in LC) Net sales split 2019 23% 77% Drug Substances Drug Products 20
Business Development Net sales (in CHF million) 900 833.5 794.3 750.5 800 717.7 700 600 480.6 500 400 315.3 300 200 100 0 2014 2015 2016 2017 2018 2019 21
Business Development Share price development from January 1, 2015 to December 31, 2019 22
Recommend
More recommend
